Adrenal MRI: Techniques and clinical applications

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 2, 2012, Pages 272-285

  Siegelman, Evan S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adrenal adenoma; adrenal gland; chemical shift imaging; pheochromocytoma

Indexed keywords

GADOLINIUM; HYDROCORTISONE; IODINE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX HYPERFUNCTION; ADRENAL DISEASE; ADRENAL INCIDENTALOMA; ADRENAL MYELOLIPOMA; ADRENAL TUMOR; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

ADRENAL GLAND DISEASES; ADRENAL GLANDS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING;

EID: 84864246820     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23601     Document Type: Review

References (125)

1. Blake MA, Cronin CG, Boland GW,. Adrenal imaging. AJR Am J Roentgenol 2010; 194: 1450-1460.
2. Boland GW,. Adrenal imaging: why, when, what, and how? Part 1. Why and when to image? AJR Am J Roentgenol 2010; 195: W377-381.
3. Boland GW,. Adrenal imaging: why, when, what, and how? Part 3. The algorithmic approach to definitive characterization of the adrenal incidentaloma. AJR Am J Roentgenol 2011; 196: W109-111.
4. Boland GW,. Adrenal imaging: why, when, what, and how? Part 2. What technique? AJR Am J Roentgenol 2011; 196: W1-5.
5. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW,. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008; 249: 756-775.
6. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010; 7: 754-773.
7. Merkle EM, Schindera ST,. MR imaging of the adrenal glands: 1.5T versus 3T. Magn Reson Imaging Clin N Am 2007; 15: 365-372, vii. (Pubitemid 47430003)
8. Schindera ST, Soher BJ, Delong DM, Dale BM, Merkle EM,. Effect of echo time pair selection on quantitative analysis for adrenal tumor characterization with in-phase and opposed-phase MR imaging: initial experience. Radiology 2008; 248: 140-147.
9. Tsushima Y, Dean PB,. Characterization of adrenal masses with chemical shift MR imaging: how to select echo times. Radiology 1995; 195: 285-286.
10. Yamashita Y, Yamamoto H, Namimoto T, Abe Y, Takahashi M,. Phased array breath-hold versus non-breath-hold MR imaging of focal liver lesions: a prospective comparative study. J Magn Reson Imaging 1997; 7: 292-297. (Pubitemid 28356960)
11. Mitchell DG, Crovello M, Matteucci T, Petersen RO, Miettinen MM,. Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology 1992; 185: 345-351.
12. Bilbey JH, McLoughlin RF, Kurkjian PS, et al. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. AJR Am J Roentgenol 1995; 164: 637-642.
13. Fujiyoshi F, Nakajo M, Fukukura Y, Tsuchimochi S,. Characterization of adrenal tumors by chemical shift fast low-angle shot MR imaging: comparison of four methods of quantitative evaluation. AJR Am J Roentgenol 2003; 180: 1649-1657. (Pubitemid 36687101)
14. Gabriel H, Pizzitola V, McComb EN, Wiley E, Miller FH,. Adrenal lesions with heterogeneous suppression on chemical shift imaging: clinical implications. J Magn Reson Imaging 2004; 19: 308-316. (Pubitemid 38294771)
15. Haider MA, Ghai S, Jhaveri K, Lockwood G,. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology 2004; 231: 711-716. (Pubitemid 38668087)
16. Israel GM, Korobkin M, Wang C, Hecht EN, Krinsky GA,. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 2004; 183: 215-219. (Pubitemid 38789040)
17. Jhaveri KS, Wong F, Ghai S, Haider MA,. Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules. AJR Am J Roentgenol 2006; 187: 1303-1308. (Pubitemid 44630836)
18. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200: 743-747. (Pubitemid 26282274)
19. Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995; 197: 411-418.
20. Namimoto T, Yamashita Y, Mitsuzaki K, et al. Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas. Radiology 2001; 218: 642-646. (Pubitemid 32172541)
21. Outwater EK, Siegelman ES, Huang AB, Birnbaum BA,. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 1996; 200: 749-752. (Pubitemid 26282275)
22. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG,. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. AJR Am J Roentgenol 1995; 165: 579-583.
23. Rescinito G, Zandrino F, Cittadini G Jr, Santacroce E, Giasotto V, Neumaier CE,. Characterization of adrenal adenomas and metastases: correlation between unenhanced computed tomography and chemical shift magnetic resonance imaging. Acta Radiol 2006; 47: 71-76. (Pubitemid 43177533)
24. Savci G, Yazici Z, Sahin N, Akgoz S, Tuncel E,. Value of chemical shift subtraction MRI in characterization of adrenal masses. AJR Am J Roentgenol 2006; 186: 130-135. (Pubitemid 46100373)
25. Halefoglu AM, Yasar A, Bas N, Ozel A, Erturk SM, Basak M,. Comparison of computed tomography histogram analysis and chemical-shift magnetic resonance imaging for adrenal mass characterization. Acta Radiol 2009; 50: 1071-1079.
26. Basaran C, Karcaaltincaba M, Akata D, et al. Fat-containing lesions of the liver: cross-sectional imaging findings with emphasis on MRI. AJR Am J Roentgenol 2005; 184: 1103-1110. (Pubitemid 43821883)
27. Martin J, Sentis M, Zidan A, et al. Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 1995; 195: 125-130.
28. Outwater EK, Bhatia M, Siegelman ES, Burke MA, Mitchell DG,. Lipid in renal clear cell carcinoma: detection on opposed-phase gradient-echo MR images. Radiology 1997; 205: 103-107. (Pubitemid 27415133)
29. Sydow BD, Rosen MA, Siegelman ES,. Intracellular lipid within metastatic hepatocellular carcinoma of the adrenal gland: a potential diagnostic pitfall of chemical shift imaging of the adrenal gland. AJR Am J Roentgenol 2006; 187: W550-551.
30. Kreft B, Zhou H, Albers P,. [Adrenal gland metastasis of clear-cell renal cell carcinoma: a diagnostic problem in chemical-shift MRT imaging.] Rofo 2003; 175: 1275-1277. (Pubitemid 37214269)
31. Shinozaki K, Yoshimitsu K, Honda H, et al. Metastatic adrenal tumor from clear-cell renal cell carcinoma: a pitfall of chemical shift MR imaging. Abdom Imaging 2001; 26: 439-442. (Pubitemid 32565879)
32. Ho LM, Paulson EK, Brady MJ, Wong TZ, Schindera ST,. Lipid-poor adenomas on unenhanced CT: does histogram analysis increase sensitivity compared with a mean attenuation threshold? AJR Am J Roentgenol 2008; 191: 234-238. (Pubitemid 351955200)
33. Johnson PT, Horton KM, Fishman EK,. Adrenal imaging with multidetector CT: evidence-based protocol optimization and interpretative practice. Radiographics 2009; 29: 1319-1331.
34. Kamiyama T, Fukukura Y, Yoneyama T, Takumi K, Nakajo M,. Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol. Radiology 2009; 250: 474-481.
35. Perri M, Erba P, Volterrani D, et al. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. AJR Am J Roentgenol 2011; 197: 209-216.
36. Cyran KM, Kenney PJ, Memel DS, Yacoub I,. Adrenal myelolipoma. AJR Am J Roentgenol 1996; 166: 395-400. (Pubitemid 26036304)
37. Kenney PJ, Wagner BJ, Rao P, Heffess CS,. Myelolipoma: CT and pathologic features. Radiology 1998; 208: 87-95. (Pubitemid 28323314)
38. Pereira JM, Sirlin CB, Pinto PS, Casola G,. CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics 2005; 25: 69-85. (Pubitemid 40186941)
39. Rao P, Kenney PJ, Wagner BJ, Davidson AJ,. Imaging and pathologic features of myelolipoma. Radiographics 1997; 17: 1373-1385. (Pubitemid 127466061)
40. Hood MN, Ho VB, Smirniotopoulos JG, Szumowski J,. Chemical shift: the artifact and clinical tool revisited. Radiographics 1999; 19: 357-371.
41. Elsayes KM, Mukundan G, Narra VR, et al. Adrenal masses: MR imaging features with pathologic correlation. Radiographics 2004; 24 () Suppl 1: S73-86. (Pubitemid 39457244)
42. Krebs TL, Wagner BJ,. MR imaging of the adrenal gland: radiologic-pathologic correlation. Radiographics 1998; 18: 1425-1440. (Pubitemid 128467068)
43. Bazot M, Boudghene F, Billieres P, Antoine J, Uzan S, Bigot J,. Value of fat-suppression gradient-echo MR imaging in the diagnosis of ovarian cystic teratomas. Clin Imaging 2000; 24: 146-153. (Pubitemid 32012484)
44. Outwater EK, Blasbalg R, Siegelman ES, Vala M,. Detection of lipid in abdominal tissues with opposed-phase gradient-echo images at 1.5 T: techniques and diagnostic importance. Radiographics 1998; 18: 1465-1480. (Pubitemid 128467071)
45. Siegelman ES, Outwater EK, Vinitski S, Mitchell DG,. Fat suppression by saturation/opposed-phase hybrid technique: spin echo versus gradient echo imaging. Magn Reson Imaging 1995; 13: 545-548.
46. Baker ME, Blinder R, Spritzer C, Leight GS, Herfkens RJ, Dunnick NR,. MR evaluation of adrenal masses at 1.5 T. AJR Am J Roentgenol 1989; 153: 307-312. (Pubitemid 19198012)
47. Kier R, McCarthy S,. MR characterization of adrenal masses: field strength and pulse sequence considerations. Radiology 1989; 171: 671-674. (Pubitemid 19134919)
48. Bittencourt LK, Matos C, Coutinho AC Jr,. Diffusion-weighted magnetic resonance imaging in the upper abdomen: technical issues and clinical applications. Magn Reson Imaging Clin N Am 2011; 19: 111-131.
49. Qayyum A,. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics 2009; 29: 1797-1810.
50. Koh DM, Collins DJ,. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-1635. (Pubitemid 46866868)
51. Miller FH, Wang Y, McCarthy RJ, et al. Utility of diffusion-weighted MRI in characterization of adrenal lesions. AJR Am J Roentgenol 2010; 194: W179-185.
52. Tsushima Y, Takahashi-Taketomi A, Endo K,. Diagnostic utility of diffusion-weighted MR imaging and apparent diffusion coefficient value for the diagnosis of adrenal tumors. J Magn Reson Imaging 2009; 29: 112-117.
53. Sandrasegaran K, Patel AA, Ramaswamy R, et al. Characterization of adrenal masses with diffusion-weighted imaging. AJR Am J Roentgenol 2011; 197: 132-138.
54. Leroy-Willig A, Roucayrol JC, Luton JP, Courtieu J, Niesenbaum N, Louvel A,. In vitro adrenal cortex lesions characterization by NMR spectroscopy. Magn Reson Imaging 1987; 5: 339-344. (Pubitemid 17167622)
55. Faria JF, Goldman SM, Szejnfeld J, et al. Adrenal masses: characterization with in vivo proton MR spectroscopyâinitial experience. Radiology 2007; 245: 788-797. (Pubitemid 350127349)
56. Kim S, Salibi N, Hardie AD, et al. Characterization of adrenal pheochromocytoma using respiratory-triggered proton MR spectroscopy: initial experience. AJR Am J Roentgenol 2009; 192: 450-454.
57. Sangwaiya MJ, Boland GW, Cronin CG, Blake MA, Halpern EF, Hahn PF,. Incidental adrenal lesions: accuracy of characterization with contrast-enhanced washout multidetector CTâ10-minute delayed imaging protocol revisited in a large patient cohort. Radiology 2010; 256: 504-510.
58. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222: 629-633. (Pubitemid 34215205)
59. Foti G, Faccioli N, Manfredi R, Mantovani W, Mucelli RP,. Evaluation of relative wash-in ratio of adrenal lesions at early biphasic CT. AJR Am J Roentgenol 2010; 194: 1484-1491.
60. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR,. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217: 798-802.
61. Park BK, Kim CK, Kim B, Lee JH,. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology 2007; 243: 760-765. (Pubitemid 46799430)
62. Krestin GP, Freidmann G, Fishbach R, Neufang KF, Allolio B,. Evaluation of adrenal masses in oncologic patients: dynamic contrast-enhanced MR vs CT. J Comput Assist Tomogr 1991; 15: 104-110.
63. Krestin GP, Steinbrich W, Friedmann G,. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology 1989; 171: 675-680. (Pubitemid 19134920)
64. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011; 259: 117-126.
65. Wehrl HF, Sauter AW, Judenhofer MS, Pichler BJ,. Combined PET/MR imagingâtechnology and applications. Technol Cancer Res Treat 2010; 9: 5-20.
66. Dunnick NR, Korobkin M,. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol 2002; 179: 559-568. (Pubitemid 34919559)
67. Siegelman ES,. MR imaging of the adrenal neoplasms. Magn Reson Imaging Clin N Am 2000; 8: 769-786.
68. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A,. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009; 23: 233-243.
69. Young WF Jr,. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610. (Pubitemid 46220820)
70. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-870.
71. Shen WT, Sturgeon C, Duh QY,. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol 2005; 89: 186-192. (Pubitemid 40315915)
72. O'Neill CJ, Spence A, Logan B, et al. Adrenal incidentalomas: risk of adrenocortical carcinoma and clinical outcomes. J Surg Oncol 2010; 102: 450-453.
73. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003; 138: 424-429. (Pubitemid 36262654)
74. Song JH, Chaudhry FS, Mayo-Smith WW,. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol 2008; 190: 1163-1168. (Pubitemid 351684914)
75. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644.
76. Mazzaglia PJ, Vezeridis MP,. Laparoscopic adrenalectomy: balancing the operative indications with the technical advances. J Surg Oncol 2010; 101: 739-744.
77. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58: 609-615.
78. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S,. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009; 161: 513-527.
79. Lenders JW, Eisenhofer G, Mannelli M, Pacak K,. Phaeochromocytoma. Lancet 2005; 366: 665-675. (Pubitemid 41176020)
80. Plouin PF, Amar L, Lepoutre C,. Phaeochromocytomas and functional paragangliomas: clinical management. Best Pract Res Clin Endocrinol Metab 2010; 24: 933-941.
81. Manger WM,. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 2006; 1073: 1-20. (Pubitemid 44911993)
82. Cohen DL, Fraker D, Townsend RR,. Lack of symptoms in patients with histologic evidence of pheochromocytoma: a diagnostic challenge. Ann N Y Acad Sci 2006; 1073: 47-51. (Pubitemid 44911997)
83. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR,. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-340. (Pubitemid 38528713)
84. Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, et al. 1,111 patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors. Ann N Y Acad Sci 2006; 1073: 38-46. (Pubitemid 44911996)
85. Messerli FH, Loughlin KR, Messerli AW, Welch WR,. The president and the pheochromocytoma. Am J Cardiol 2007; 99: 1325-1329.
86. Sutton MG, Sheps SG, Lie JT,. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 1981; 56: 354-360. (Pubitemid 11093806)
87. Opocher G, Schiavi F,. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 2010; 24: 943-956.
88. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466. (Pubitemid 34755714)
89. Barontini M, Dahia PL,. VHL disease. Best Pract Res Clin Endocrinol Metab 2010; 24: 401-413.
90. Elsayes KM, Menias CO, Siegel CL, Narra VR, Kanaan Y, Hussain HK,. Magnetic resonance characterization of pheochromocytomas in the abdomen and pelvis: imaging findings in 18 surgically proven cases. J Comput Assist Tomogr 2010; 34: 548-553.
91. Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol 2003; 181: 1663-1668. (Pubitemid 37466549)
92. Lee TH, Slywotzky CM, Lavelle MT, Garcia RA,. Cystic pheochromocytoma. Radiographics 2002; 22: 935-940.
93. Blake MA, Kalra MK, Maher MM, et al. Pheochromocytoma: an imaging chameleon. Radiographics 2004; 24 (Suppl 1): S87-99. (Pubitemid 39457245)
94. Park BK, Kim CK, Kwon GY, Kim JH,. Re-evaluation of pheochromocytomas on delayed contrast-enhanced CT: washout enhancement and other imaging features. Eur Radiol 2007; 17: 2804-2809. (Pubitemid 47603975)
95. Choyke PL, Doppman JL,. Case 18: adrenocorticotropic hormone-dependent Cushing syndrome. Radiology 2000; 214: 195-198. (Pubitemid 30019891)
96. Newell-Price J,. Diagnosis/differential diagnosis of Cushing's syndrome: a review of best practice. Best Pract Res Clin Endocrinol Metab 2009; 23 (Suppl 1): S5-14.
97. Orth DN,. Cushing's syndrome. N Engl J Med 1995; 332: 791-803.
98. Ichiyanagi O, Sasagawa I, Izumi T, et al. Relationship between clear cell/compact cell ratio and computed tomographic attenuation number in adrenocortical adenoma. Int Urol Nephrol 1999; 31: 585-590. (Pubitemid 30179113)
99. Choyke PL,. Commentary on "Computed tomography in the diagnosis of adrenal disease" and "Nonfunctioning adrenal masses: incidental discovery on computed tomography." AJR Am J Roentgenol 2009; 192: 568-570.
100. Krikorian A, Khan M,. Is metabolic syndrome a mild form of Cushing's syndrome? Rev Endocr Metab Disord 2010; 11: 141-145.
101. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95: 2736-2745.
102. Law K, Brunt EM,. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14: 591-604.
103. Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003; 149: 543-548. (Pubitemid 38054698)
104. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A,. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006; 30: 872-878. (Pubitemid 43724119)
105. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136.
106. Fassnacht M, Allolio B,. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 273-289.
107. Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol 2011; 196: W706-714.
108. Schlund JF, Kenney PJ, Brown ED, Ascher SM, Brown JJ, Semelka RC,. Adrenocortical carcinoma: MR imaging appearance with current techniques. J Magn Reson Imaging 1995; 5: 171-174.
109. Mackay B, el-Naggar A, Ordonez NG,. Ultrastructure of adrenal cortical carcinoma. Ultrastruct Pathol 1994; 18: 181-190. (Pubitemid 24131626)
110. Chiche L, Dousset B, Kieffer E, Chapuis Y,. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 2006; 139: 15-27. (Pubitemid 41814428)
111. Cicala MV, Mantero F,. Primary aldosteronism: what consensus for the diagnosis. Best Pract Res Clin Endocrinol Metab 2010; 24: 915-921.
112. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050. (Pubitemid 38368386)
113. Lingam RK, Sohaib SA, Vlahos I, et al. CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. AJR Am J Roentgenol 2003; 181: 843-849. (Pubitemid 37021865)
114. Kahn SL, Angle JF,. Adrenal vein sampling. Tech Vasc Interv Radiol 2010; 13: 110-125.
115. Schwab CW, 2nd, Vingan H, Fabrizio MD,. Usefulness of adrenal vein sampling in the evaluation of aldosteronism. J Endourol 2008; 22: 1247-1250. (Pubitemid 351913480)
116. Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wangberg B,. Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol 2010; 36: 699-704.
117. Mourra N, Hoeffel C, Duvillard P, Guettier C, Flejou JF, Tiret E,. Adrenalectomy for clinically isolated metastasis from colorectal carcinoma: report of eight cases. Dis Colon Rectum 2008; 51: 1846-1849.
118. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M,. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285. (Pubitemid 37304697)
119. Pantalone KM, Gopan T, Remer EM, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract 2010; 16: 577-587.
120. Gufler H, Eichner G, Grossmann A, et al. Differentiation of adrenal adenomas from metastases with unenhanced computed tomography. J Comput Assist Tomogr 2004; 28: 818-822. (Pubitemid 39488561)
121. Paulsen SD, Nghiem HV, Korobkin M, Caoili EM, Higgins EJ,. Changing role of imaging-guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies. AJR Am J Roentgenol 2004; 182: 1033-1037. (Pubitemid 38391670)
122. Mazzaglia PJ, Monchik JM,. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg 2009; 144: 465-470.
123. Craig WD, Fanburg-Smith JC, Henry LR, Guerrero R, Barton JH,. Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation. Radiographics 2009; 29: 261-290.
124. Ellingson JJ, Coakley FV, Joe BN, Qayyum A, Westphalen AC, Yeh BM,. Computed tomographic distinction of perirenal liposarcoma from exophytic angiomyolipoma: a feature analysis study. J Comput Assist Tomogr 2008; 32: 548-552.
125. Israel GM, Bosniak MA, Slywotzky CM, Rosen RJ,. CT differentiation of large exophytic renal angiomyolipomas and perirenal liposarcomas. AJR Am J Roentgenol 2002; 179: 769-773. (Pubitemid 34919596)